Literature DB >> 25561803

Perceived risk as a barrier to appropriate diagnosis of irritable bowel syndrome.

Eunmi Ahn1, Ki Young Son1, Dong Wook Shin1, Min Kyu Han1, Hyejin Lee1, Ah Reum An1, Eun Ho Kim1, BeLong Cho1.   

Abstract

AIM: To evaluate perceived risk, diagnostic testing, and acceptance of a diagnosis of irritable bowel syndrome (IBS) among the Korean laypersons.
METHODS: We designed a conceptual framework to evaluate the health-seeking behavior of subjects based on a knowledge, attitude, and practice model. We developed a vignette-based questionnaire about IBS based on a literature review and focused group interviews. The vignette described a 40-year-old woman who meets the Rome III criteria for IBS without red-flag signs. It was followed by questions about demographic characteristics, health behaviors, IBS symptoms, risk perception, perceived need for diagnostic tests, and acceptance of a positive diagnosis of IBS. We planned a nationwide survey targeting laypersons without IBS and between the ages of 20 and 69 years. Survey participants were selected by quota sampling stratified by gender, age, and nationwide location. A multivariate logistic model was constructed based on literature reviews, univariate analysis, and a stepwise selection method to investigate correlations between the perceived risk, need for diagnostic tests, and acceptance of a positive diagnosis.
RESULTS: Of 2354 eligible households, 1000 subjects completed the survey and 983 subjects were analyzed, excluding those who met symptom criteria for IBS. After reading the IBS vignette, the majority of subjects (86.8%) responded that the patient was at increased risk of severe disease. The most frequent concern was colon cancer (59.8%), followed by surgical condition (51.5%). Most subjects responded the patient needs diagnostic tests (97.2%). Colonoscopy was the most commonly required test (79.5%). Less than half of the respondents requested a stool examination (45.0%), blood test (40.7%), abdominal ultrasound (36.0%), or computed tomography (20.2%). The subjects who felt increased risk were more likely to see a need for colonoscopy [adjusted odds ratio (aOR) = 2.10, 95%CI: 1.38-3.18]. When asked about the positive diagnosis, the most frequent response was that "the patient would not be reassured" (65.7%). The increased risk perception group was less likely to be reassured by a positive diagnosis of IBS, compared to the other respondents (aOR = 0.52, 95%CI: 0.34-0.78).
CONCLUSION: For IBS diagnosis, increased risk perception is a possible barrier to the appropriate use of diagnostic tests and to the patient's acceptance of a positive diagnosis.

Entities:  

Keywords:  Diagnostic testing; Functional gastrointestinal disease; Irritable bowel syndrome; Patient attitude; Positive diagnosis

Mesh:

Year:  2014        PMID: 25561803      PMCID: PMC4277973          DOI: 10.3748/wjg.v20.i48.18360

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Why do dyspeptic patients over the age of 50 consult their general practitioner? A qualitative investigation of health beliefs relating to dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1998-08       Impact factor: 5.386

2.  The perfect storm of overutilization.

Authors:  Ezekiel J Emanuel; Victor R Fuchs
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

3.  Overview of the National Cancer screening programme and the cancer screening status in Korea.

Authors:  Yeonju Kim; Jae Kwan Jun; Kui Sun Choi; Hoo-Yeon Lee; Eun-Cheol Park
Journal:  Asian Pac J Cancer Prev       Date:  2011

Review 4.  Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors.

Authors:  N A Koloski; N J Talley; P M Boyce
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

5.  Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts.

Authors:  Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2010-03-02       Impact factor: 10.864

6.  Medical and lay views of irritable bowel syndrome.

Authors:  M Dixon-Woods; S Critchley
Journal:  Fam Pract       Date:  2000-04       Impact factor: 2.267

Review 7.  Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective.

Authors:  Surinder K Dhaliwal; Richard H Hunt
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 2.566

8.  The structure of lay consultation networks: managing illness in community settings.

Authors:  Eleanor Palo Stoller; Amy A Wisniewski
Journal:  J Aging Health       Date:  2003-08

9.  Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology.

Authors:  Rachel E Casiday; A P S Hungin; Charles S Cornford; Niek J de Wit; Mwenza T Blell
Journal:  Fam Pract       Date:  2008-11-14       Impact factor: 2.267

10.  Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls--eight years follow-up of IBS patients in primary care.

Authors:  Åshild Faresjö; Ewa Grodzinsky; Claes Hallert; Toomas Timpka
Journal:  BMC Public Health       Date:  2013-09-11       Impact factor: 3.295

View more
  2 in total

1.  Clinical study of anesthetization by dezocine combined with propofol for indolent colonoscopy.

Authors:  Bin-Bin Xu; Xiao-Liang Zhao; Gui-Ping Xu
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 2.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.